# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K112422   
B. Purpose for Submission: To obtain substantial equivalence for a modification to add CSF to the original 510(k) device which detects Cryptococcal Antigen.   
C. Measurand: Capsular polysaccharide antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii)   
D. Type of Test: Qualitative and semi-quantitative dipstick sandwich lateral flow immunochromatographic assay   
E. Applicant: Immuno-Mycologics, Inc.   
F. Proprietary and Established Names: CrAg Lateral Flow Assay   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GMD</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>866.3165</td><td rowspan=1 colspan=1>83-Microbiology</td></tr></table>

# H. Intended Use:

1. Intended use:

The CrAg Lateral Flow Assay is an immunochromatographic test system for the qualitative or semi-quantitative detection of the capsular polysaccharide antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii) in serum and cerebral spinal fluid (CSF).

2. Indication for use:

The $\mathrm { C r A g }$ Lateral Flow Assay is an immunochromatographic test system for the qualitative or semi-quantitative detection of capsular polysaccharide antigens of Cryptococcus species complex (Cryptococcus neoformans and Cryptococcus gattii) in serum, and cerebral spinal fluid (CSF).

The CrAg Lateral Flow Assay is a prescription use laboratory assay which can aid in the diagnosis of cryptococcosis

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Not applicable

# I. Device Description:

The CrAg Lateral Flow Assay is a dipstick sandwich immunochromatographic assay which detects cryptococcal antigen in cerebral spinal fluid (CSF). The assay consists of CrAg Lateral Flow test strips which have a gold-conjugated antibody and a goldconjugated, anti-cryptococcal antibody deposited onto a sample membrane and antiCrypto antibody and control-line capture antibody striped onto a membrane. The kit also includes a specimen diluent.

# J. Substantial Equivalence Information:

1. Predicate Device name Immuno-Mycologics’ CrAg Lateral Flow Assay

2. Predicate K number: K102286

Comparison with predicate:

Table 1: Comparison Between New Device and Predicate Device   

<table><tr><td rowspan=1 colspan=3>SIMILARITIESFeature        CrAg LFA (New Device  K112422)        CrAg LFA (Serum Only) (K102286)</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Indication ForUse</td><td rowspan=1 colspan=1>Prescription-use laboratory assay, whichcan aid in the diagnosis of cryptococcosis</td><td rowspan=1 colspan=1>Prescription-use laboratory assay, whichcan aid in the diagnosis of cryptococcosis</td></tr><tr><td rowspan=1 colspan=3>DeviceDescription</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Lateral Flow Assay</td><td rowspan=1 colspan=1>Lateral Flow Assay</td></tr><tr><td rowspan=1 colspan=1>Instruments</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>None</td></tr><tr><td rowspan=1 colspan=1>AssayComponents</td><td rowspan=1 colspan=1>Specimen diluent, lateral flow strips, built-in control, gold conjugated antibodies</td><td rowspan=1 colspan=1>Specimen diluent, lateral flow strips, built-in control, gold conjugated antibodies</td></tr><tr><td rowspan=1 colspan=1>SpecimenPre-Treatment</td><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Dilution</td></tr><tr><td rowspan=1 colspan=1>DetectionAntibody</td><td rowspan=1 colspan=1>Anti-cryptococcal monoclonal antibody</td><td rowspan=1 colspan=1>Anti-cryptococcal monoclonal antibody</td></tr><tr><td rowspan=1 colspan=1>StorageRequirements</td><td rowspan=1 colspan=1>20-25°C</td><td rowspan=1 colspan=1>20-25°C</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=2>DIFFERENCESCryptococcal Antigen Lateral Flow:       Cryptococcal Antigen Lateral Flow:New Device - K112422                       Serum Only - K102286</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended UseSampleMatrix</td><td rowspan=1 colspan=1>Immunochromatographic test system forthe qualitative or semi-quantitativedetection of capsular polysaccharideantigens of Cryptococcus species complex(Cryptococcus neoformans andCryptococcus gatti) in serum and CSFCSF</td><td rowspan=1 colspan=1>Immunochromatographic test system for thequalitative or semi-quantitative detection ofcapsular polysaccharide antigens ofCryptococcus species complex(Cryptococcus neoformans andCryptococcus gatti) in serumSerum</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not Applicable

# L. Test Principle:

The $\mathrm { C r A g }$ Lateral Flow Assay is a dipstick sandwich immunochromatographic assay, which detects cryptococcal antigen in CSF. For the qualitative procedure, specimens are diluted 1:2 in 1x Specimen Diluent and analyzed. For the semiquantitative procedure, specimens are diluted 1:5 in 1x Specimen Diluent followed by 1:2 serial dilutions. All dilutions are then analyzed as in the qualitative procedure. Specimens are placed into an appropriate reservoir, such as a test tube or microtiter plate, and the lateral flow device is then placed into the reservoir allowing the specimen to come into contact with the test membrane. The test uses specimen wicking to capture gold-conjugated, anti-cryptococcal monoclonal antibodies and gold-conjugated control antibodies that are deposited onto a membrane. If cryptococcal antigen is present in the specimen, it binds to the gold–conjugated, anti-cryptococcal antibodies. The gold-labeled antibodyantigen complex will continue to wick up the membrane where it will interact with the Test Line (T). The Test Line is immobilized anti-cryptococcal monoclonal antibodies. If the specimen contains cryptococcal antigen, a sandwich is created with the gold-labeled antibodies and the immobilized antibodies, causing a visible line to develop at the test line site (T). If proper flow occurs and the reagents are reactive at the time of use, the wicking of any specimen, positive or negative, will cause the gold-conjugated control goat IgG antibody to move to the Control Line (C) which is immobilized bovine anti-goat IgG antibody. The immobilized anti-goat antibody will bind to the goldconjugated goat IgG Control antibody and will cause a visible line to develop (C). A positive test result will create two lines, while a negative test result will create one line (Figure 1). If the control line fails to develop a line, then the test is not valid.

![](images/14cb263372acabce9e70c878390d982cbcf239194afe585592a1233273275c78.jpg)  
Figure1. CrAg Lateral Flow Assay Schematic

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

The CrAg Lateral Flow Assay was evaluated for reproducibility and precision by spiking mock CSF samples with cryptococcal antigen to produce a panel consisting of a negative sample, a high-negative $\left( \mathbf { C } _ { 5 } \right)$ sample, a low-positive sample and a moderate-positive sample. This panel was tested twice per day at three sites with a total of five operators over a five-day period in order to determine both the inter-lab and the intra-lab reproducibility and precision of the assay. The results of this study are shown in the tables below.

Table 2. Repeatability at 3 Different Sites   

<table><tr><td rowspan=1 colspan=1>CSFPANEL</td><td rowspan=1 colspan=1>Site 1% Pos</td><td rowspan=1 colspan=1>Site 2% Pos</td><td rowspan=1 colspan=1>Site 3% Pos</td><td rowspan=1 colspan=1>Overall% Pos</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0%(0/30)</td><td rowspan=1 colspan=1>0%(0/30)</td><td rowspan=1 colspan=1>0%(0/15)</td><td rowspan=1 colspan=1>0%(0/75)</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>10%(3/30)</td><td rowspan=1 colspan=1>0%(0/30)</td><td rowspan=1 colspan=1>0%(0/15)</td><td rowspan=1 colspan=1>3%(2/75)</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>100%(30/30)</td><td rowspan=1 colspan=1>100%(30/30)</td><td rowspan=1 colspan=1>100%(15/15)</td><td rowspan=1 colspan=1>100%(75/75)</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>100%(30/30)</td><td rowspan=1 colspan=1>100%(30/30)</td><td rowspan=1 colspan=1>100%(15/15)</td><td rowspan=1 colspan=1>100%(75/75)</td></tr></table>

# b. Linearity/assay reportable range:

Not Applicable

# c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Real time stability testing is on-going. Initial accelerated stability was determined by testing three lots of kits stored at $2 5 \mathrm { { ^ \circ C } }$ (real-time) for 18 months and $3 7 ^ { \circ } \mathrm { C }$ (accelerated) for 12 months. LF specimen Diluent was spiked with cryptococcal antigen at four concentrations: 1.5, 3.0, 6.0 and $9 . 0 \mathrm { n g / m l }$ . Non-spiked diluent was used as a negative control. Each sample was tested in triplicate by one operator. Each spiked sample replicate tested positive and each negative control tested negative on all lots of the $\mathrm { C r A g }$ Lateral Flow kits, stored at both $2 5 \mathrm { { ^ \circ C } }$ and $3 7 ^ { \circ } \mathrm { C }$ after storage for six months. At 12 months, all samples passed on all kits stored at $2 5 \mathrm { { ^ \circ C } }$ . Kits stored at $3 7 ^ { \circ } \mathrm { C }$ were not tested. This initial data in addition to established stability of currently available lateral flow tests indicate that the $\mathrm { C r A g }$ Lateral Flow test kit is stable at room temperature for 18 months.

# d. Detection limit:

# Detection Limit/Analytical Cut-off

Analytical sensitivity for the $\mathrm { C r A g }$ Lateral Flow Assay was estimated by running varying concentrations of cryptococcal antigen diluted in LF Specimen Diluent. The concentration where $50 \%$ of the results were positive and $50 \%$ of the results were negative determined our analytical cut-off. The analytical cut-off is $1 . 2 5 \mathrm { n g / m l }$ .

Table 3. Analytical Cut-Off   

<table><tr><td rowspan=1 colspan=1>Sample Concentration (ng/ml)</td><td rowspan=1 colspan=1>No. Positive</td><td rowspan=1 colspan=1>No. Tested % Positive</td><td rowspan=1 colspan=1>No. Tested % Positive</td></tr><tr><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>17%</td></tr><tr><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>50%</td></tr><tr><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>88%</td></tr><tr><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2.00</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>3.00</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>100%</td></tr></table>

# Analytical specificity:

Analytical specificity for the $\mathrm { C r A g }$ Lateral Flow Assay was determined by evaluating potentially cross-reacting medical conditions unrelated to cryptococcosis. Specimens were tested in triplicate. Percent positive was determined for each condition (Table 3).

Table 3. Analytical Specificity   

<table><tr><td rowspan=1 colspan=1>Pathology</td><td rowspan=1 colspan=1># of Samples</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Penicilliosis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0 % (0/5)</td></tr><tr><td rowspan=1 colspan=1>Sporothrichosis</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0 % (0/6)</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0 % (0/5)</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0 % (0/5)</td></tr><tr><td rowspan=1 colspan=1>Mycoplasmosis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0 % (0/7)</td></tr><tr><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Blastomycosis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Coccidiomycosis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Histoplasmosis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Candidiasis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr><tr><td rowspan=1 colspan=1>Aspergillus GM+</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10 % (1/10)</td></tr><tr><td rowspan=1 colspan=1>RheumatoidFactor*</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 % (0/10)</td></tr></table>

\* Rheumatoid factor concentrations tested ranged from $1 1 2 \mathrm { I U / m l }$ to 6479IU/mls.

Additionally, cross-reactivity was assessed by testing crude culture filtrate antigens at a range of concentrations using the $\mathrm { C r A g }$ Lateral Flow Assay at high concentrations $\mathrm { ( > 0 . 1 \ m g / m l ) }$ , antigens from Paracoccidiodes brasiliensis exhibitied some cross-reactivity. Antigens from Aspergillus terreus, Aspergillus fumigatus, Aspergillus niger, and Aspergillus flavus did not exhibit cross-reactivity.

The assay was not evaluated for cross-reactivity against the following organisms or pathologies:

Pneumocystis carinii Trichosporon beigelii Zygomycetes Antinuclear antibody $^ +$ Hepatitis A Virus Hepatitis C Virus

Candida dubliniensis Candida tropicalis   
Candida parapsidosis Candida krusei   
Candida glabrata   
Cladosporium   
trichoides   
Neisseria   
meningitidis   
Salmonella typhi   
Mycobacterium   
tuberculosis   
Enterovirus   
Enterobacteriaceae Enterococcus spp.   
Epstein Barr   
Trichosporon beigelii

Staphylococcus spp.

Streptococcus pneumonia Streptococcus spp. Diphtheroid H. influenzae type B Herpes simplex viruses Listeria monocytogenes Syneresis fluid condensation Staphylococcus aureus

The assay was not evaluated for potential interference related to specimen pretreatment with 2-mercaptoethanol or with specimens including the following substances: bloody CSF, cloudy CSF, white blood cells, xanthochromic CSF, bilirubin, protein, systemic lupus erythmatosus (SLE), sarcoidosis, or N.memingitides.

The effect of pronase on the CrAg LFA was determined by pronase-treating five Cryptococcal EIA positive specimens and five Cryptococcal EIA negative specimens. The samples were analyzed both untreated and pronase-treated. All treated, positives samples remained positive and all treated, negative samples remained negative. Therefore, pronase does not affect the CrAg LFA.

2. Comparison studies:   
a. Method comparison with predicate device: Not Applicable

b. Matrix comparison: A matrix comparison study was performed on 86 paired serum and CSF specimen that were collected prospectively. Percent agreement positive is $100 \%$ . Percent agreement negative is $8 8 . 9 \%$ , and overall agreement is $9 6 . 5 \%$ . Of the 3 discrepant results, one patient was diagnosed with cryptococcal meningitis approximately 5- 6 week after the LFA was performed.

# 3. Clinical studies:

The $\mathrm { C r A g }$ Lateral Flow Assay was compared to the standard reference method for diagnoses of cryptococcosis (culture and/or India Ink) to evaluate the sensitivity and specificity of the assay. These studies contained prospective specimens. A summary of the data collected is included in the following table.

<table><tr><td rowspan="3">CSF CrAg LFA</td><td colspan="3">Culture/India Ink</td></tr><tr><td></td><td>Positive</td><td>Negative</td></tr><tr><td>Positive</td><td>65</td><td>1</td></tr><tr><td>Assay</td><td>Negative</td><td>0</td><td>77</td></tr></table>

<table><tr><td rowspan=1 colspan=1>CSF</td><td rowspan=1 colspan=1>Calculated</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>94.4% -100%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>93.1% -99.8%</td></tr></table>

4. Clinical cut-off:

Not Applicable

5. Expected values/Reference range:

The frequency of cryptococcosis is dependent on several factors including: patient population, type of institution, and epidemiology. In this study, $100 \%$ (65/65) of true positives as determined by culture and/or India Ink were detected. The apparent false positive in the $\mathrm { C r A g }$ LFA, compared to culture/India ink, could be the result of $\mathrm { C r A g }$ detection having a higher sensitivity $( 1 0 0 \% )$ than culture $( 8 3 \% )$ and India ink $( 8 4 \% )$ . Therefore, it is expected to have culture/India Ink negative/LFA positive results.

# N. Proposed Labeling:

The labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.